Ratings BioInvent International AB

Equities

BINV

SE0015244520

Market Closed - Nasdaq Stockholm Other stock markets 11:29:34 2024-05-20 am EDT			5-day change	1st Jan Change
29.55 ^SEK	-1.34%		+13.44%	+55.85%

May. 14	Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL	CI
May. 03	Bioinvent International AB Resolves to Elect Laura Lassouw-Polman as New Board Member	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIOINVENT INTERNATIONAL AB	+55.85%	182M	C+
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B	B+
ARGENX SE	-2.59%	21.6B	B
BIONTECH SE	-12.38%	22.31B	B+
GENMAB A/S	-5.29%	19.19B	A-
BEIGENE, LTD.	-3.35%	18.23B	B
WUXI APPTEC CO., LTD.	-38.57%	17.62B	A-
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B	C+
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes